Why do some men get worse/more hot flashes than others?

A newly published study in the Journal of Urology has suggested that men with certain genetic polymorphisms, of younger age, and of lower body mass index are at greater risk for hot flashes than control subjects when being treated with androgen deprivation therapy (ADT). … READ MORE …

Final CHAARTED data now published in NEJM

The final results of the CHAARTED trial, recommending early treatment with the combination of androgen deprivation therapy (ADT) and chemotherapy, at least in men with extensive metastasis at diagnosis, have just been published this week by Sweeney et al. in The New England Journal of Medicine (NEJM). … READ MORE …

Chemo + ADT + RT: no benefit after 10 years

Earlier this month, we looked at the evidence of benefit for adding chemotherapy to androgen deprivation therapy (ADT) + radiation therapy (RT) for high-risk prostate cancer (see “Docetaxel with radiation in prostate cancer treatment”). … READ MORE …

Should all patients starting on ADT be on a statin too?

A newly published article in JAMA Oncology has now suggested that adding a statin to a patient’s treatment regimen at initiation of androgen deprivation therapy (ADT) may significantly impact time to disease progression among men diagnosed with progressive, hormone-sensitive prostate cancer. … READ MORE …

Combining ADT and salvage radiation therapy improves outcomes

For the first time, a randomized clinical trial (GETUG-AFU 16) has proved that adding a short course of androgen deprivation therapy (ADT) to salvage radiation therapy (sRT) improves the progression-free survival over sRT alone. … READ MORE …

Adding docetaxel to ADT and radiation therapy for high-risk prostate cancer

Earlier today, at the annual meeting of the American Society of Clinical Oncology (ASCO), we were given the results of RTOG 0521 — a large, randomized trial of adding docetaxel chemotherapy to androgen deprivation therapy (ADT) and radiation therapy for men with high-risk prostate cancer. … READ MORE …

Low dose rate brachytherapy monotherapy across risk groups

New registry data from the Cleveland Clinic shows good oncological control with low dose rate brachytherapy (LDRBT) monotherapy, at least for low-risk and low  intermediate-risk groups. This is the first time I’ve seen LDRBT monotherapy data for higher-risk groups. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,295 other followers